Comparative Pharmacology
Head-to-head clinical analysis: FETZIMA versus MILNACIPRAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETZIMA versus MILNACIPRAN HYDROCHLORIDE.
FETZIMA vs MILNACIPRAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fetzima (levomilnacipran) is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine, with approximately 2-fold higher potency for norepinephrine reuptake inhibition, which enhances neurotransmission in the central nervous system.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with approximately 3-fold higher potency for norepinephrine reuptake inhibition compared to serotonin. It does not significantly affect dopamine or other neurotransmitter reuptake.
20 mg orally once daily for 2 days, then 40 mg once daily for 2 days, then 80 mg once daily for 2 days, then 120 mg once daily; maximum dose 120 mg/day.
50 mg orally twice daily with food, increased to 100 mg twice daily based on tolerability and efficacy.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours for levomilnacipran; at steady state, half-life supports once-daily dosing without extensive accumulation.
Terminal elimination half-life is approximately 6-8 hours in young adults; prolonged to 10-15 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 65% as unchanged levomilnacipran and 25% as N-desmethyllevomilnacipran); fecal excretion accounts for ~8%.
Primarily renal: ~60% excreted unchanged in urine; ~23% as glucuronide conjugates; ~3% as other metabolites; biliary/fecal excretion accounts for <5%.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant